UBS Group Reiterates “€125.00” Price Target for Bayer (FRA:BAYN)

UBS Group set a €125.00 ($154.32) target price on Bayer (FRA:BAYN) in a research report report published on Monday, February 5th, www.boersen-zeitung.de reports. The firm currently has a buy rating on the healthcare company’s stock.

Other research analysts also recently issued research reports about the stock. Sanford C. Bernstein set a €129.00 ($159.26) target price on shares of Bayer and gave the stock a buy rating in a research note on Friday, October 13th. equinet set a €118.00 ($145.68) target price on shares of Bayer and gave the stock a buy rating in a research note on Friday, October 13th. Commerzbank set a €124.00 ($153.09) target price on shares of Bayer and gave the stock a buy rating in a research note on Friday, October 13th. JPMorgan Chase & Co. reiterated a buy rating and issued a target price on shares of Bayer in a research note on Friday, October 13th. Finally, Baader Bank set a €140.00 ($172.84) target price on shares of Bayer and gave the stock a buy rating in a research note on Thursday, October 26th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of €121.71 ($150.26).

Bayer (FRA:BAYN) opened at €97.54 ($120.42) on Monday. The stock has a market cap of $81,670.00 and a P/E ratio of 23.06. Bayer has a 52 week low of €93.30 ($115.19) and a 52 week high of €123.82 ($152.86).

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/13/bayer-bayn-given-a-125-00-price-target-at-ubs-group.html.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply